Jan. 5, 2024—Bristol Myers Squibb, GSK and Novo Nordisk are the newest members of the Alliance for Genomic Discovery.
Nov. 15, 2023—A study by Vanderbilt researchers found that more than half of the patients who receive the results of genetic tests might not be impelled to seek more services than they're already receiving.
Nov. 14, 2023—The first fruits of a landmark academic-industry partnership that is harvesting the depth and breadth of the human genome to better understand and treat disease will become available to researchers in the spring of 2024.
Jan. 9, 2023—Nashville Biosciences LLC, a wholly owned subsidiary of Vanderbilt University Medical Center, and Illumina Inc., a global leader in DNA sequencing and array-based technologies, today announced an agreement with Amgen, a global biopharmaceutical company, to whole-genome sequence approximately 35,000 DNA samples.
Dec. 19, 2022—BioVU, Vanderbilt University Medical Center’s biobank, has reached another milestone — deep-freeze storage of more than 300,000 biological samples.
Nashville Biosciences and Illumina announce agreement to establish preeminent clinico-genomic resource for life sciences research & development
Jan. 10, 2022—Nashville Biosciences, a wholly-owned subsidiary of Vanderbilt University Medical Center, has announced an agreement with Illumina, a leading genomic technology company, to realize the full potential of VUMC’s DNA databank, BioVU.
Jan. 5, 2022—A folic acid-like drug changed a DNA process within brain tumors of glioblastoma patients, according to results from a phase 1 clinical trial.
Dec. 16, 2021—Vanderbilt research is blazing a trail for the application of game theory to genomic and health data reidentification risk.
Sep. 30, 2021—Vanderbilt-Ingram Cancer Center research is providing new insights into how genetic variants convey breast cancer susceptibility by altering the transcription factor proteins that convert DNA strands into RNA.